Signaturefd LLC Buys 9,454 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Signaturefd LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,077 shares of the biopharmaceutical company’s stock after buying an additional 9,454 shares during the period. Signaturefd LLC’s holdings in Pfizer were worth $2,257,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Edgestream Partners L.P. increased its stake in shares of Pfizer by 612.7% in the first quarter. Edgestream Partners L.P. now owns 342,794 shares of the biopharmaceutical company’s stock worth $8,686,000 after purchasing an additional 294,696 shares during the period. Leelyn Smith LLC increased its stake in shares of Pfizer by 6.7% in the first quarter. Leelyn Smith LLC now owns 93,608 shares of the biopharmaceutical company’s stock worth $2,372,000 after purchasing an additional 5,841 shares during the period. Mitchell Mcleod Pugh & Williams Inc. increased its stake in shares of Pfizer by 4.0% in the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 34,457 shares of the biopharmaceutical company’s stock worth $873,000 after purchasing an additional 1,331 shares during the period. Florida Financial Advisors LLC bought a new position in shares of Pfizer in the first quarter worth about $246,000. Finally, Bleakley Financial Group LLC increased its stake in shares of Pfizer by 21.7% in the first quarter. Bleakley Financial Group LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,593,000 after purchasing an additional 18,268 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Morgan Stanley lifted their price objective on Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 30th. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. Citigroup lifted their target price on Pfizer from $23.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.55.

View Our Latest Stock Report on Pfizer

Pfizer Stock Down 1.2%

NYSE PFE opened at $25.36 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock’s 50 day moving average is $23.92 and its two-hundred day moving average is $24.77. The company has a market capitalization of $144.15 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 0.93 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.82 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.78%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).